Diagnostic work up for sarcoidosis. Think of CVID as an important differential @RheumNow #ACR2024 #sarcoidosis https://t.co/DvJzkN3ZjY

• https://x.com/synovialjoints/status/1857436677913923992/photo/1

RA pearls from #ACR24 review course: 1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi. 2. Multimorbidity=Poor outcomes, High risk for mortality. 3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg

• https://x.com/AdelaCastro222/status/1857575812788040158/photo/1
• https://x.com/AdelaCastro222/status/1857575812788040158/photo/1

Myths by Daniel Clauw Small fiber neuropathy - misnomer, non-specific, not worth getting a skin biopsy Fibromyalgia is not autoimmune - it is nociplastic pain and treated differently #ACR24 Review Course @RheumNow https://t.co/JLyfnfMBML

• https://x.com/ericdeinmd/status/1857448282550583347/photo/1

Pathophysiology of calcinosis. Antonia Valenzuela at Review Course @RheumNow #ACR24 https://t.co/gSJSa2lGXw

• https://x.com/synovialjoints/status/1857462981778432015/photo/1

Risk factors and crystal composition of in calcinosis. In SSc - calcinosis is assc with vasculopathy, dz duration #ACR24 #ACRReview https://t.co/LJvrdVG1jg

• https://x.com/KDAO2011/status/1857456780076372017/photo/1

Infection as a Cause of Death https://t.co/CwvffN7CcM https://t.co/SwSuAanuEO

• Infection as a Cause of Death | RheumNow

RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty

Diagnosis and Management of Kawasaki Disease The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki… https://t.co/rS5bDneplO https://t.co/nZ0GeIQD0T

Recomendations for the management of Kawasaki’s disease. Cardiometabolic session, Bryce Binstadt @RheumNow #ACR24 https://t.co/KftwMDYzH1

• https://x.com/synovialjoints/status/1857503756310687955/photo/1

#Baricitinib in refractory #myositis? A ‘weak’ trial design comparing #Bari to #Bari Rx started 12 weeks later in a small N =15 neat idea but NO answer 👇 looked like 👍 it worked BUT this is not the #RCT design that can show differences #ACR24 @RheumNow abst#1731 @ACRheum

No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse… https://t.co/XY0UVDTAI6 https://t.co/b09FB3niNP

Multimorbidity reduces response to b/tsDMARDs in RA. We can make a difference by treating the whole person! Amazing talk by Dr Iain McInned to wrap up #ACR24 #ReviewCourse. @RheumNow https://t.co/NiaUXzt4nT

• https://x.com/JihaRheum/status/1857486092846473222/photo/1

⭐️Top tip from Dr Laura Carbone: 🦴Rule out hypophosphatasia before starting bisphosphonate or denosumab in patients with low ALP #ACR24 @RheumNow

Pain in PsA = predictor of disability and QoL TYK-2 inhibition lowered clinical pain outcomes and ALSO pain-associated biomarkers vs PBO @RheumNow #ACR24 Abstract #2366 https://t.co/DAgmdmmTE0

• https://x.com/Dr_Brian_MD/status/1857432793917030906/photo/1